Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
(Baltimore, MD--May 14, 2013) Noxilizer, Inc., the company behind the unique and superior, room temperature
NO2-based sterilization technology for life science manufacturers and hospitals,
announced today the appointment of Mr. David Chaskin as CFO.
Mr. Chaskin, the first of several planned hires to support Noxilizer’s expansion and will
be responsible for all aspects of the company's finance and accounting. President and
CEO, Larry Bruder said, “Noxilizer is poised for growth. We have a clear
commercialization plan and David will be a key member of our leadership team in
support of our plan and advancing NO2 sterilization in the global marketplace. David has
a deep knowledge of finance, accounting, and operations and understands how to take
organizations to the next level.”
Mr. Chaskin brings over 25 years of accounting and financial reporting experience in a
variety of strategic and financial executive roles. Most recently, he served as CFO for
Aritas Group, Inc., a financial holding company, and the Financial and Operations
Principal for the US broker dealer subsidiary, Aritas Securities LLC. Mr. Chaskin joined
Aritas Group, Inc. a few months after its initial product launch and helped it grow into a
company that achieved tens of millions of dollars of revenue. Prior to Aritas, he held a
variety of financial roles for large, publicly-traded companies including Chemical Bank,
Guess? and TBA Entertainment, and lead financial positions with smaller, privately-held
Of the opportunity, Mr. Chaskin notes “Noxilizer, Inc. has a solid financial position, and is
bringing a superior offering to the sterilization marketplace. There is incredible
opportunity as the commercial team articulates the advantages of NO2 sterilization and
delivers on customer needs, to grow revenue and build shareholder value.” The only
room temperature sterilization solution, NO2 sterilization is highly-compatible with a wide
range of drug-device products, and provides a safer, simpler, more economical
alternative for manufacturers.
Also in support of the increased commercial activities, Noxilizer recently relocated to a
16,000 square foot office and laboratory space at the University of Maryland BioPark. “Our new lab space allows us to respond to a growing number of inquiries for feasibility
studies, increasing demand for our contract sterilization services, and ramp up
production of the RTS 360 Industrial NO2 Sterilizer.” says Bruder. Additionally, it
provides Noxilizer growing room as we advance our hospital program.”
Noxilizer’s new headquarters is located at 800 West Baltimore Street, Suite 151
Baltimore, MD 21201.
About Noxilizer, Inc.:
Noxilizer has a unique and superior room temperature NO2-based sterilization
technology that is revolutionizing two major sterilization markets — medical device/
pharmaceutical/biotechnology manufacturing and hospitals. In the manufacturing
market, Noxilizer provides sterilization services for medical devices and drug/device
combination products. Noxilizer sells the RTS 360 Industrial NO2 Sterilizer to companies
who sterilize products in-house and also offers contract sterilization services. In
hospitals, Noxilizer is developing a system especially for sensitive, high-tech equipment
used in minimally-invasive surgical procedures. Noxilizer is headquartered in Baltimore,
MD with offices in the US and Japan. Noxilizer, Inc. is privately held and was founded in
2004. For more information about Noxilizer, please visit: www.noxilizer.com.
C (574) 304-1502
Help employers find you! Check out all the jobs and post your resume.